Hydroxychloroquine in Hospitalized Patients with COVID-19 : Real-World Experience Assessing Mortality
© 2020 Pharmacotherapy Publications, Inc..
INTRODUCTION: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial.
OBJECTIVES: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up.
METHODS: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.
RESULTS: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages ± SD were 62.3 ± 15.9 years (53.7% male) and 61.9 ± 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7).
CONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Pharmacotherapy - 40(2020), 11 vom: 12. Nov., Seite 1072-1081 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Annie, Frank H [VerfasserIn] |
---|
Links: |
---|
Themen: |
4QWG6N8QKH |
---|
Anmerkungen: |
Date Completed 04.12.2020 Date Revised 12.11.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/phar.2467 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316138304 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316138304 | ||
003 | DE-627 | ||
005 | 20231225160430.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/phar.2467 |2 doi | |
028 | 5 | 2 | |a pubmed24n1053.xml |
035 | |a (DE-627)NLM316138304 | ||
035 | |a (NLM)33044019 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Annie, Frank H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hydroxychloroquine in Hospitalized Patients with COVID-19 |b Real-World Experience Assessing Mortality |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.12.2020 | ||
500 | |a Date Revised 12.11.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Pharmacotherapy Publications, Inc. | ||
520 | |a INTRODUCTION: Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial | ||
520 | |a OBJECTIVES: We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up | ||
520 | |a METHODS: This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded | ||
520 | |a RESULTS: Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages ± SD were 62.3 ± 15.9 years (53.7% male) and 61.9 ± 16.0 years (53.0% male) in the HCQ and no-HCQ groups, respectively. There was no difference in overall 30-day mortality between the HCQ and no-HCQ groups (HCQ 13.1%, n=367; no HCQ 13.6%, n=367; odds ratio 0.95, 95% confidence interval 0.62-1.46) after propensity matching. Although statistically insignificant, the HCQ-azithromycin (AZ) group had an overall mortality rate of 14.6% (n=199) compared with propensity-matched no-HCQ-AZ cohort's rate of 12.1% (n=199, OR 1.24, 95% CI 0.70-2.22). Importantly, however, there was no trend in this cohort's overall mortality/arrhythmogenesis outcome (HCQ-AZ 17.1%, no HCQ-no AZ 17.1%; OR 1.0, 95% CI 0.6-1.7) | ||
520 | |a CONCLUSIONS: We report from a large retrospective multinational database analysis of COVID-19 outcomes with HCQ and overall mortality in hospitalized patients. There was no statistically significant increase in mortality and mortality-arrhythmia with HCQ or HCQ-AZ | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Antimalarial | |
650 | 4 | |a azithromycin | |
650 | 4 | |a coronavirus | |
650 | 4 | |a hydroxychloroquine | |
650 | 4 | |a macrolide | |
650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
650 | 7 | |a Hydroxychloroquine |2 NLM | |
650 | 7 | |a 4QWG6N8QKH |2 NLM | |
700 | 1 | |a Sirbu, Cristian |e verfasserin |4 aut | |
700 | 1 | |a Frazier, Keely R |e verfasserin |4 aut | |
700 | 1 | |a Broce, Mike |e verfasserin |4 aut | |
700 | 1 | |a Lucas, B Daniel |c Jr |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 40(2020), 11 vom: 12. Nov., Seite 1072-1081 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2020 |g number:11 |g day:12 |g month:11 |g pages:1072-1081 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/phar.2467 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 2020 |e 11 |b 12 |c 11 |h 1072-1081 |